ライフサイエンスコーパス: cystectomy

1 mbers of patients who are not candidates for cystectomy.

2 is an acceptable alternative to open radical cystectomy.

3 ng other patients toxic effects and delay to cystectomy.

4 rging minimally invasive approach to radical cystectomy.

5 abstracts related to robot-assisted radical cystectomy.

6 he scientific practice of LND during radical cystectomy.

7 ved convalescence compared with open-radical cystectomy.

8 ve complications with robot-assisted radical cystectomy.

9 logic outcomes as compared with open radical cystectomy.

10 d a retrospective comparison to open radical cystectomy.

11 combination chemotherapy followed by radical cystectomy.

12 ible, minimally invasive approach to radical cystectomy.

13 d outcomes related to robot-assisted radical cystectomy.

14 patients underwent FDG-PET/CT before planned cystectomy.

15 spared the unnecessary morbidity of radical cystectomy.

16 in making treatment decisions before radical cystectomy.

17 an achieve survival rates similar to radical cystectomy.

18 tine, doxorubicin, and cisplatin followed by cystectomy.

19 egies particularly as they relate to radical cystectomy.

20 gement of muscle invasive disease is radical cystectomy.

21 ogic outcomes compare well with open radical cystectomy.

22 e disease continues to be managed by radical cystectomy.

23 nitial experiences with laparoscopic radical cystectomy.

24 (2003-2012) treated with chemotherapy and/or cystectomy.

25 5-year disease recurrence risk after radical cystectomy.

26 a viable option for some patients who refuse cystectomy.

27 s are markers of improved outcome of radical cystectomy.

28 determined before, during, and after radical cystectomy.

29 mine the stage of the disease before radical cystectomy.

30 al recurrence (LR) in all patients receiving cystectomy.

31 Of these 2 patients, one required radical cystectomy.

32 bladder cancer who were treated with radical cystectomy.

33 own to correlate with survival after radical cystectomy.

34 invasive bladder cancer who received radical cystectomy.

35 bladder cancer who were treated with radical cystectomy.

36 xorubicin, and cisplatin followed by radical cystectomy.

37 to T4a) and were to be treated with radical cystectomy.

38 on bladder tumor, most still require radical cystectomy.

39 s in the bladder, and survival after salvage cystectomy.

40 Those with less than a CR underwent cystectomy.

41 bladder from patients that underwent radical cystectomy.

42 carcinoma of the urinary bladder is radical cystectomy.

43 partial cystectomy, and 17 elected a radical cystectomy.

44 moradiation (six patients) went to immediate cystectomy.

45 etained bladders than in those who underwent cystectomy.

46 a total of 37 of 91 patients (40%) required cystectomy.

47 ents with residual tumor underwent immediate cystectomy.

48 ment complications (n = 1) underwent salvage cystectomy.

49 were unable or unwilling to undergo radical cystectomy.

50 considerable debate about the role of early cystectomy.

51 noma of the bladder have poor survival after cystectomy.

52 patients are unwilling or unable to undergo cystectomy.

53 of concerns regarding toxicity and delay to cystectomy.

54 dMVAC were administered, followed by radical cystectomy.

55 nd counseling of patients undergoing radical cystectomy.

56 utilized to measure HRQOL following radical cystectomy.

57 important outcome measure following radical cystectomy.

58 rizable urinary reservoirs following radical cystectomy.

59 ctures per 100 person-years in those without cystectomy.

60 elvic lymphadenectomy at the time of radical cystectomy.

61 ence of chronic kidney damage after subtotal cystectomy.

62 orting the use of minimally invasive radical cystectomy.

63 curative therapeutic alternatives to radical cystectomy.

64 evaluated from 1 to 26 weeks after subtotal cystectomy.

65 e timing of intravesical therapy and radical cystectomy.

66 in young animals at 26 weeks after subtotal cystectomy.

67 ain a complication within 90 days of radical cystectomy.

68 analysis included 31,191 colectomies, 2,670 cystectomies, 1,514 pancreatectomies, 2,607 proctectomie

69 Four thousand nine hundred forty cystectomies, 1,573 esophagectomies, 20,362 lung resecti

70 Of the 17 patients who had radical cystectomy, 11 (65%) are alive.

71 ity for pancreatectomy (67% of the decline), cystectomy (37%), and esophagectomy (32%), but not for t

72 our understanding of HRQOL following radical cystectomy, a lack of prospective studies limits conclus

73 with no residual muscle-invasive disease at cystectomy after neoadjuvant chemotherapy were likely to

74 tors influence bladder cancer outcomes after cystectomy, after adjustment for pathologic factors and

75 Thirty-six patients (34%) underwent cystectomy, all with evidence of tumor activity, includi

76 eveloped metastases and thus did not undergo cystectomy; all others (n = 43) proceeded to cystectomy

77 d benefits of radical cystectomy over simple cystectomy alone are accepted, an optimal template for p

78 enefit of adjuvant chemotherapy over radical cystectomy alone for muscle-invasive bladder cancer.

79 In cisplatin-ineligible patients, radical cystectomy alone is recommended.

80 sease) and were randomly assigned to radical cystectomy alone or three cycles of methotrexate, vinbla

81 The crude 5-year OS for chemotherapy alone, cystectomy alone, preoperative chemotherapy followed by

82 Compared with cystectomy alone, preoperative chemotherapy was associat

83 As compared with radical cystectomy alone, the use of neoadjuvant methotrexate, v

84 orable clinical outcomes relative to radical cystectomy alone.

85 rapy alone was worse than those treated with cystectomy alone.

86 ficant improvement in survival compared with cystectomy alone.

87 rowth and experience in laparoscopic radical cystectomy, along with continuing refinements in techniq

88 N1, 48%; cN2, 45%; cN3, 7%), 1,104 underwent cystectomy and 635 were treated with chemotherapy alone.

89 T1 or worse, we recommended patients undergo cystectomy and adjuvant chemotherapy.

90 o evidence of an interaction between radical cystectomy and age, sex, comorbidity score, or cancer st

91 e versus deferred chemotherapy after radical cystectomy and bilateral lymphadenectomy for patients wi

92 ical outcomes of patients treated by radical cystectomy and bilateral lymphadenectomy for urothelial-

93 de positive (pN1-3) M0 disease after radical cystectomy and bilateral lymphadenectomy, with no eviden

94 Neoadjuvant therapy before cystectomy and consolidation therapy with biological age

95 ues has prompted interest in robotic radical cystectomy and extended PLND, and recent reports have de

96 ive morbidity following contemporary radical cystectomy and identify preoperative, intraoperative, an

97 We assessed whether radical cystectomy and intestinal urinary diversion are associat

98 omparison between minimally invasive radical cystectomy and open radical cystectomy is needed to defi

99 on to technique, especially in nerve-sparing cystectomy and orthotopic cystoplasty may reduce the rat

100 ne, doxorubicin, and cisplatin) plus radical cystectomy and pelvic lymph node dissection.

101 Radical cystectomy and pelvic lymphadenectomy (PLND) remains the

102 hat may benefit from integrated therapy with cystectomy and perioperative systemic chemotherapy.

103 mally invasive techniques to perform radical cystectomy and PLND have been adopted.

104 consisting of patients treated with radical cystectomy and PLND.

105 We evaluated the association between radical cystectomy and risk of fracture at any site, controlling

106 inent diversion can decrease the interval to cystectomy and therefore may impact positively on surviv

107 ry protocols for patients undergoing radical cystectomy and urinary diversion and describe our unique

108 atients with bladder cancer who have radical cystectomy and urinary diversion are at increased risk o

109 ical prostatectomy), bladder cancer (radical cystectomy and urinary diversion for muscle invasive bla

110 Radical cystectomy and urinary diversion may cause chronic metab

111 tolerated and effective alternative to open cystectomy and urinary diversion.

112 included 50,520 patients, of whom 4,878 had cystectomy and urinary diversion.

113 urothelial cancer of the bladder treated by cystectomy and/or radiotherapy.

114 uccessfully treated with salvage therapy via cystectomy, and 16 patients (16%) died of disease.

115 d follow-up with TUR alone, 15 had a partial cystectomy, and 17 elected a radical cystectomy.

116 46 percent for esophagectomy, 39 percent for cystectomy, and 24 percent for lung resection.

117 alone, preoperative chemotherapy followed by cystectomy, and cystectomy followed by adjuvant chemothe

118 oung) and 12 months (old) underwent subtotal cystectomy, and then were evaluated from 1 to 26 weeks a

119 tomy are lacking, minimally invasive radical cystectomy appears to have superior perioperative outcom

120 ostatectomy and reconstruction after radical cystectomy are discussed.

121 Although rigorous comparisons with open cystectomy are lacking, minimally invasive radical cyste

122 rm outcomes after minimally invasive radical cystectomy are limited, intermediate term oncologic outc

123 ve, randomized comparisons with open radical cystectomy are needed as this technique continues to be

124 ized prospective comparisons to open radical cystectomy are needed to further validate this procedure

125 management of the urethra before and during cystectomy as well as afterwards.

126 iveness and harms of both minimally invasive cystectomy as well as the optimal extent of pelvic lymph

127 Thirteen patients underwent cystectomy at intervals that ranged from 1.5 to 38 month

128 extirpative portion of laparoscopic radical cystectomy at multiple institutions.

129 This result is similar to cystectomy-based studies for patients of similar age and

130 onary resection, hepatectomy, colectomy, and cystectomy) between 2010 and 2012 were identified from t

131 At 26 weeks after subtotal cystectomy, bladder capacity in young animals was indist

132 edures (pancreatic resection, esophagectomy, cystectomy), but longer for other procedures (aortic and

133 Morbidity is common following radical cystectomy, but careful attention to preoperative, intra

134 ion in those undergoing laparoscopic radical cystectomy, but these observations have not been corrobo

135 e last year, numerous robot-assisted radical cystectomy case series with larger cohorts have been pub

136 approach the yield seen at high-volume open cystectomy centers, but a larger proportion of robotic l

137 c survival compared with the high-expression cystectomy cohort (69.9% versus 53.8% 3-year CSS, P = 0.

138 However, in the cystectomy cohort (n = 88), MRE11 expression was not ass

139 Neoadjuvant chemotherapy before cystectomy confers a survival benefit in bladder cancer,

140 1.21; 95% CI, 1.10 to 1.32) compared with no cystectomy, controlling for patient and disease characte

141 While radical cystectomy cures many patients with this tumor, almost 5

142 Institutional radical cystectomy databases containing detailed information on

143 zed trial comparing open and robotic radical cystectomy demonstrated equivalent lymph node yields.

144 affect treatment as feasibility for radical cystectomy depends on staging by a combination of clinic

145 Patients undergoing colectomy, cystectomy, esophagectomy, gastrectomy, hysterectomy, lu

146 ) after six cancer surgeries (prostatectomy, cystectomy, esophagectomy, pancreatectomy, pneumonectomy

147 nd variant histology should be offered early cystectomy, especially if harboring pure squamous, adeno

148 n be considered as an alternative to radical cystectomy, especially in elderly patients not well suit

149 th lymph node-positive disease after radical cystectomy, even in the context of adjuvant chemotherapy

150 In patients undergoing cystectomy, evidence supports the need for an adequate l

151 ive chemotherapy followed by cystectomy, and cystectomy followed by adjuvant chemotherapy was 14% (95

152 otherapy, or, alternatively, to have initial cystectomy followed by five cycles of adjuvant chemother

153 bilateral pelvic lymphadenectomy and radical cystectomy for bladder cancer (median follow-up, 101 mon

154 spective study of 958 patients who underwent cystectomy for bladder cancer between 1984 and 2003.

155 ed quality of life (HRQOL) following radical cystectomy for bladder cancer is an important outcome me

156 Minimally invasive radical cystectomy for bladder cancer is performed laparoscopica

157 uggests that all patients undergoing radical cystectomy for bladder cancer should undergo concomitant

158 ram predicting recurrence risk after radical cystectomy for bladder cancer.

159 gastrectomy, colectomy, lung resection, and cystectomy for cancer from 2003 through 2007 were studie

160 glucose (FDG) in patients undergoing radical cystectomy for cT2-3N0M0 urothelial carcinoma of the bla

161 c splenic procedures were performed: splenic cystectomy for epithelial (4) or traumatic (2) cyst, and

162 and overall survival in patients who undergo cystectomy for invasive bladder cancer and are node-nega

163 xpression and overall survival after radical cystectomy for invasive bladder cancer.

164 l and quality of life of patients undergoing cystectomy for invasive bladder cancer.

165 oscopy, recurrence, resections, and possible cystectomy for progression to invasive cancers.

166 le-invasive bladder cancer (MIBC), reserving cystectomy for salvage treatment.

167 nimally invasive alternative to open radical cystectomy for the treatment of bladder cancer.

168 No patient required cystectomy for treatment-related bladder morbidity.

169 had no residual disease than patients in the cystectomy group (38 percent vs. 15 percent, P<0.001).

170 The incidence of fracture in the cystectomy group was 6.55 fractures per 100 person-years

171 A significant regionalization of cystectomy has already been established.

172 dissection performed at the time of radical cystectomy has an ability to improve locoregional diseas

173 eutic role of lymphadenectomy during radical cystectomy has become apparent and recent work has attem

174 However, the risk of fractures after radical cystectomy has not been defined.

175 ent of the urethra before, during, and after cystectomy, however, is still not standardized.

176 erative outcomes are as good as open radical cystectomy if not better.

177 adiation therapy, chemotherapy) with salvage cystectomy, if necessary, can achieve survival rates sim

178 sacrectomy in 170 patients (32%), and total cystectomy in 105 patients (20%).

179 tein expression to predict outcome following cystectomy in 257 patients enrolled in two independent c

180 otherapy may be offered as an alternative to cystectomy in appropriately selected patients with MIBC

181 .60-0.75) for prediction of nodal disease at cystectomy in AUO-AB-05/95.

182 an achieve similar lymph node counts as open cystectomy in experienced hands and with careful patient

183 lso help define selection criteria for early cystectomy in HGT1 bladder cancer, particularly for pati

184 o emerge and appears similar to open-radical cystectomy in nonrandomized comparisons.

185 Radiotherapy is an alternative to cystectomy in patients with muscle-invasive bladder canc

186 based combination chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial

187 Ten-year survival can still be achieved with cystectomy in the face of grossly positive lymph nodes i

188 f approximately 70% of the bladder (subtotal cystectomy) in 12-week-old female rats induced complete

189 Reasons for cystectomy included presumed evidence of tumor growth fr

190 xorubicin, and cisplatin followed by radical cystectomy increases the likelihood of eliminating resid

191 are limited data on robotic assisted radical cystectomy, initial reports suggest that an appropriate

192 lymph node dissection at the time of radical cystectomy is a crucial component of the surgical manage

193 Radical cystectomy is a morbid procedure with rather long hospit

194 Robot-assisted radical cystectomy is a reproducible, minimally invasive approac

195 espond to intravesical agents, in whom early cystectomy is advocated.

196 Robot-assisted radical cystectomy is an emerging minimally invasive approach to

197 Laparoscopic radical cystectomy is being increasingly performed at several ce

198 Robot-assisted radical cystectomy is being more widely studied as a potential a

199 invasive radical cystectomy and open radical cystectomy is needed to define the role of these modalit

200 ents with MIBC and in some patients for whom cystectomy is not an option.

201 finements in technique, laparoscopic radical cystectomy is now being performed at many centers worldw

202 most important predictor of recurrence after cystectomy is pathologically positive nodes, our aim was

203 Robot-assisted radical cystectomy is steadily growing with a feasible learning

204 The prevalence of robot-assisted radical cystectomy is steadily increasing.

205 sus adjuvant chemotherapy around the time of cystectomy is still debated, though the best level-one e

206 sus adjuvant chemotherapy around the time of cystectomy is still debated.

207 Minimally invasive radical cystectomy is technically feasible.

208 Early cystectomy is the standard of care for BCG failure; howe

209 Radical cystectomy is the standard of care for patients who fail

210 ined-modality therapy, with chemotherapy and cystectomy, is associated with the best outcomes.

211 it is superseding pure laparoscopic radical cystectomy (LRC) at centers, where robot is available an

212 as unrelated to mortality for esophagectomy, cystectomy, lung resection, aortic valve replacement, or

213 Radical cystectomy may include resection of adjacent organs and

214 15 (38%; 95% CI, 23% to 53%) showing pT0 at cystectomy, meeting the primary end point of the study.

215 gical efficacy of minimally invasive radical cystectomy (MIRC) and PLND.

216 For patients unwilling or unable to undergo cystectomy, numerous local therapies exist, although few

217 Thirteen patients required a salvage cystectomy, of whom 6 died, which includes 4 (9%) from a

218 or burden, defined as the receipt of radical cystectomy or >/= 50 Gy of radiation therapy delivered t

219 tools developed to help stratify patients to cystectomy or bladder-sparing regimens.

220 cancer, 151 were treated by standard radical cystectomy or by definitive TUR, if restaging TUR of the

221 py of his primary bladder tumor with radical cystectomy or radiation.

222 viewed as state of the art, as compared with cystectomy or radiotherapy alone, for deeply invasive bl

223 Open radical cystectomy (ORC) and pelvic lymph node dissection (PLND)

224 Although the added benefits of radical cystectomy over simple cystectomy alone are accepted, an

225 ed with 71% of 52 patients who had immediate cystectomy (P: = .3).

226 ancer outcome in patients undergoing radical cystectomy, p53 is the strongest predictor, followed by

227 rysm repair, carotid endarterectomy, radical cystectomy, pancreatic resection, and esophagectomy.

228 Of the cystectomy patients, 363 received preoperative and 328 r

229 with radical radiotherapy and one cohort of cystectomy patients.

230 ications for improving perioperative care of cystectomy patients.

231 Within 90 days of cystectomy, patients were centrally randomly assigned (1

232 ence suggests that outcome is improved after cystectomy performed at high-volume centers and by high-

233 mpare the effectiveness of cystectomy versus cystectomy plus adjuvant chemotherapy in real-world pati

234 ladder neck contracture postprostatectomy or cystectomy presents a reconstructive challenge combined

235 tered markers in patients treated by radical cystectomy provides prognostic information that could he

236 ples for technique of robot-assisted radical cystectomy (RARC) based on current peer reviewed literat

237 Robot-assisted radical cystectomy (RARC) continues to provide a minimally invas

238 and current status of robot-assisted radical cystectomy (RARC) with pelvic lymphadenectomy (PLND) and

239 Although radical cystectomy (RC) currently is viewed as the standard of c

240 neoadjuvant chemotherapy followed by radical cystectomy (RC).

241 cancer-related surgical procedures (radical cystectomy [RC], radical nephrectomy [RN], and radical p

242 oncologic outcomes with laparoscopic radical cystectomy remain undefined, and appropriate lymph node

243 Radical cystectomy remains the gold-standard therapy for invasiv

244 gement guidelines are less clear and radical cystectomy remains the mainstay of treatment at this tim

245 While radical cystectomy remains the mainstay of treatment for muscle-

246 ion of high-risk superficial bladder cancer, cystectomy remains the standard of care for the patient

247 sus adjuvant chemotherapy around the time of cystectomy remains to be resolved.

248 eumonectomy, 2 to 5 percent for gastrectomy, cystectomy, repair of a nonruptured abdominal aneurysm,

249 In patients undergoing cystectomy, reports using more standardized measures of

250 Optimal outcomes following radical cystectomy require an extended lymph node dissection, ne

251 Cystectomy salvages the majority, but not all, of relaps

252 ed immunohistochemically on archival radical cystectomy samples from 164 patients with invasive or hi

253 rates of overall survival similar to radical cystectomy series.

254 o be equivalent to contemporary open radical cystectomy series.

255 oncologic outcome data, laparoscopic radical cystectomy should be considered an investigative techniq

256 s than a T0 response but medically unfit for cystectomy (six patients), received consolidative chemor

257 lihood of eliminating residual cancer in the cystectomy specimen and is associated with improved surv

258 d with the absence of residual cancer in the cystectomy specimen.

259 perimposed histologic and genetic mapping in cystectomy specimens and was verified in urinary bladder

260 16 were performed on 234 DNA samples of five cystectomy specimens from patients with invasive bladder

261 Cystectomy specimens obtained after radical surgery were

262 Cystectomy specimens showed diminished tumor cells with

263 In cystectomy specimens, tumor cellularity was markedly red

264 long-term DSS comparable to modern immediate cystectomy studies, for patients with similarly staged M

265 Eleven patients (37%) underwent a cystectomy subsequent to gemcitabine therapy.

266 c outcomes appear comparable to open radical cystectomy, the reference standard.

267 early aggressive intervention (i.e., radical cystectomy), then treatment recommendations should refle

268 allow patient selection for radiotherapy or cystectomy, thus improving overall cure rates.

269 s ratio (OR) of 1.3 (95% CI, 0.8 to 2.3) for cystectomy to 4.9 (95% CI, 2.4 to 10.1) for pancreatecto

270 d third terciles of cost varied from 27% for cystectomy to 40% for colectomy.

271 current experience with laparoscopic radical cystectomy to identify its role in oncological bladder s

272 lymph node dissection at the time of radical cystectomy to optimize oncologic outcomes.

273 p, we sought to compare the effectiveness of cystectomy versus cystectomy plus adjuvant chemotherapy

274 or standard urothelial cell carcinoma (early cystectomy vs. intravesical therapy).

275 patients who did not have a progression or a cystectomy was 19 months (range, 2 to 35 months).

276 Median time from start of chemotherapy to cystectomy was 9.7 weeks.

277 Cystectomy was associated with a 21% greater risk of fra

278 Transplant nephrectomy with cystectomy was performed as a secondary treatment in one

279 Salvage cystectomy was performed in 6 (10.7%) of 56 patients who

280 Cystectomies were performed by 106 surgeons in 109 insti

281 t to intravesical BCG therapy and refusing a cystectomy were considered eligible for the trial.

282 Calmette-Guerin (BCG) therapy and refusing a cystectomy were considered eligible for the trial.

283 a of the bladder who were not candidates for cystectomy were eligible.

284 Radical cystectomy with an appropriate lymph node dissection and

285 All patients undergoing radical cystectomy with bilateral pelvic iliac lymphadenectomy,

286 Radical cystectomy with bilateral pelvic lymph node dissection r

287 ease in the United States centers on radical cystectomy with bilateral pelvic lymphadenectomy.

288 Laparoscopic radical cystectomy with extended lymphadenectomy provides short-

289 s regarding the clinical benefits of radical cystectomy with extended lymphadenectomy, and will also

290 urvival rates in patients undergoing radical cystectomy with extended PLND, even in cases of patholog

291 AMVAC with pegfilgrastim followed by radical cystectomy with lymph node dissection.

292 ents with invasive bladder cancer treated by cystectomy with monoclonal antibodies against the Mr 72,

293 ncer, multimodal treatment involving radical cystectomy with neoadjuvant chemotherapy offers the best

294 Radical cystectomy with pelvic lymph node dissection (PLND) is t

295 neoadjuvant chemotherapy followed by radical cystectomy with pelvic lymph node dissection, which disc

296 the current status of robot-assisted radical cystectomy with pelvic lymphadenectomy and urinary diver

297 Radical cystectomy with thorough pelvic lymphadenectomy remains

298 Robot-assisted radical cystectomy with urinary diversion appears to be growing

299 cystectomy; all others (n = 43) proceeded to cystectomy within 8 weeks after last chemotherapy admini